WallStreetZenWallStreetZen

NASDAQ: NRBO
Neurobo Pharmaceuticals Inc Stock

Open Broker Account
$1.57+0.14 (+9.79%)
Updated Dec 2, 2022
NRBO Price
$1.57
Fair Value Price
$31.88
Market Cap
$10.21M
52 Week Low
$1.13
52 Week High
$63.85
P/E
-0.1x
P/B
1.72x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$13.87M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.27
Operating Cash Flow
-$13M
Beta
0.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

NRBO Overview

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. It develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Zen Score

Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NRBO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

NRBO ($1.57) is undervalued by 95.08% relative to our estimate of its Fair Value price of $31.88 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NRBO ($1.57) is significantly undervalued by 95.08% relative to our estimate of its Fair Value price of $31.88 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NRBO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NRBO due diligence checks available for Premium users.

Be the first to know about important NRBO news, forecast changes, insider trades & much more!

NRBO News

Valuation

NRBO fair value

Fair Value of NRBO stock based on Discounted Cash Flow (DCF)
Price
$1.57
Fair Value
$31.88
Undervalued by
95.08%
NRBO ($1.57) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NRBO ($1.57) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NRBO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

NRBO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.1x
Industry
13.84x
Market
21.89x

NRBO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.72x
Industry
5.06x
NRBO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

NRBO's financial health

Profit margin

Revenue
$0.0
Net Income
-$3.1M
Profit Margin
0%
NRBO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$7.6M
Liabilities
$1.6M
Debt to equity
0.27
NRBO's short-term assets ($7.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NRBO's short-term assets ($7.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NRBO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NRBO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$2.4M
Investing
$0.0
Financing
-$134.0k
NRBO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

NRBO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
NRBO$10.21M+9.79%-0.10x1.72x
VRPX$9.96M0.00%-0.47x0.51x
LABP$9.90M+2.07%-0.18x0.22x
UNCY$10.56M-3.45%-0.69x2.28x
VBLT$10.67M0.00%0.31x0.42x

Neurobo Pharmaceuticals Stock FAQ

What is Neurobo Pharmaceuticals's quote symbol?

NASDAQ: NRBO) Neurobo Pharmaceuticals trades on the NASDAQ under the ticker symbol NRBO. Neurobo Pharmaceuticals stock quotes can also be displayed as NASDAQ: NRBO.

If you're new to stock investing, here's how to buy Neurobo Pharmaceuticals stock.

What is the 52 week high and low for Neurobo Pharmaceuticals (NASDAQ: NRBO)?

(NASDAQ: NRBO) Neurobo Pharmaceuticals's 52-week high was $63.85, and its 52-week low was $1.13. It is currently -97.54% from its 52-week high and 38.94% from its 52-week low.

How much is Neurobo Pharmaceuticals stock worth today?

(NASDAQ: NRBO) Neurobo Pharmaceuticals currently has 6,503,528 outstanding shares. With Neurobo Pharmaceuticals stock trading at $1.57 per share, the total value of Neurobo Pharmaceuticals stock (market capitalization) is $10.21M.

Neurobo Pharmaceuticals stock was originally listed at a price of $6,900.69 in Aug 5, 2016. If you had invested in Neurobo Pharmaceuticals stock at $6,900.69, your return over the last 6 years would have been -99.98%, for an annualized return of -75.29% (not including any dividends or dividend reinvestments).

How much is Neurobo Pharmaceuticals's stock price per share?

(NASDAQ: NRBO) Neurobo Pharmaceuticals stock price per share is $1.57 today (as of Dec 2, 2022).

What is Neurobo Pharmaceuticals's Market Cap?

(NASDAQ: NRBO) Neurobo Pharmaceuticals's market cap is $10.21M, as of Dec 5, 2022.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Neurobo Pharmaceuticals's market cap is calculated by multiplying NRBO's current stock price of $1.57 by NRBO's total outstanding shares of 6,503,528.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.